TwinKnowledge | $3,700,000 | (Apr 3, 2025)
experial | $2,198,930 | (Apr 3, 2025)
Certified by Founder
Lodge
Shinobi Therapeutics
start up
United States
- South San Francisco, CA
- 13/12/2023
- Series A
- $51,000,000
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
- Industry Biotechnology Research
- Website https://www.shinobitx.com/
- LinkedIn https://www.linkedin.com/company/shinobitx/about/
Related People
Dan KempFounder
United States -
New York City Metropolitan Area
Accomplished BioPharma Executive with experience in drug discovery (Novartis), translational and clinical development (Merck), sell-side, buy-side and M&A transactional BD (Takeda), Executive oversight (GammaDelta Therapeutics, Adaptate Therapeutics) and Operational Leadership (Cell Therapies at Takeda).
Cambrian Network | $5,900,000 | (Apr 3, 2025)
SchoolAI | $25,000,000 | (Apr 3, 2025)
TrialKit | $4,250,000 | (Apr 3, 2025)
Further AI | $5,000,000 | (Apr 3, 2025)
Actively AI | $22,500,000 | (Apr 3, 2025)
Ropes | $3,100,000 | (Apr 3, 2025)